PRX Related Analyst Comments

Aug 24, 2012 08:05 AM Needham & Company Maintains a 'Hold' on Par Pharmaceutical (PRX); Is Endo (ENDP) the 'Mystery Bidder'

Aug 24, 2012 07:59 AM Needham & Company on Endo Pharmaceuticals (ENDP): Watson (WPI) Gains First Generic Lidoderm Approval; A Few Other Issues Too

Jul 20, 2012 08:31 AM Needham & Company maintains a 'Strong Buy' on Mylan (MYL); PRX Grossly Undervalued by TGP, MYL/PRX Instead As Strong Combo

Jul 16, 2012 11:55 AM Par Pharmaceutical (PRX) Hugs Buyout Price as it Could See Higher Bids

May 31, 2012 02:11 PM Barclays Cuts Estimates on Par Pharmaceutical (PRX); Removing Lovaza Contribution From Model

May 30, 2012 07:36 AM Needham & Company maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Defending Core Fundamentals Despite Setback From Lovaza Litigation

May 9, 2012 12:21 PM UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Comments From Conference Call

May 9, 2012 08:14 AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Generic Core Delivers; Substantial Upside with Lovaza on Horizon

Apr 20, 2012 09:46 AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Healthy Deal with Handa

Apr 9, 2012 02:10 PM Barclays on U.S. Specialty Pharmaceuticals: Model Adjustments on MYL, PRX, TEVA, & WCRX

Feb 29, 2012 09:52 AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Strong New Product Launch Cadence & Conservative Pricing Erosion Support Upward Bias

Jan 9, 2012 10:51 AM UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Shaping Up To Be Strong Growth Story

Jan 9, 2012 08:24 AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Analyst Day Highlights Strong Generic Fundamentals, Enhanced Capability and Capacity

Jan 6, 2012 11:20 AM Needham & Company: Thoughts Heading Into Par Pharmaceutical's (PRX) January 6, Analyst Day; Generics Take Center Stage

Dec 20, 2011 08:01 AM Needham & Company: Specialty Pharmaceuticals - 2012 Preview: European Hangover Expected to Ease; Valuations Reflect Fear Not Fact

Nov 30, 2011 10:59 AM Leerink Swann Remains Positive on Shares of Par Pharmaceutical (PRX) Following Meeting With Management

Nov 3, 2011 08:10 AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); 3Q11 Meets Expectations as Key Products Continue Strong Pace

Oct 19, 2011 08:27 AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Confirms Purchase of Divested Teva-Cephalon Products for Bargain Price

Oct 10, 2011 08:06 AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Positive Outcome for Par as a Result of Teva-Cephalon Merger

Sep 7, 2011 08:38 AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Whistleblower Lawsuit Accuses Par of Illegal Drug-Switching Scheme

Jul 26, 2011 09:15 AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Threat Finally Emerges on Megace ES; Longer Term Overhang With No Immediate Bite

Jun 30, 2011 08:50 AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Zuplenz & Oravig Life Support Terminated; Restructuring Removes Overhang

May 6, 2011 01:44 PM UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Strong Generics Sales; Brands Disappoint

Mar 10, 2011 07:59 AM Jefferies Cuts Price Target on POZEN Inc. (POZN) by 28.5%, Major Patent Risk

Oct 22, 2010 11:22 AM FBR Capital Maintains a 'Market Perform' on Patriot Coal (PRX); Solid Met Coal Growth; Next Catalyst Is Operational Consistency

Jul 19, 2010 07:49 AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL) and Par Pharmaceutical (PRX)

Jul 16, 2010 12:58 PM Barclays on Specialty Pharmaceuticals: June Qtr Preview for Selected Companies

Jul 6, 2010 07:39 AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Zuplenz Approval Adds Another Product to Strativa Product Portfolio

May 27, 2010 07:56 AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Receives Final FDA Approval for Generic Zegerid

Apr 15, 2010 08:01 AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Court Invalidates Zegerid Patents; Adding more Visibility and Certainty to a Key Pipeline Opportunity

Sep 30, 2009 07:31 AM Goldman Sachs Raises Price Targets for Healthcare Services; Upgrades ABC, Downgrades PSSI